Mutant Calreticulin in the Myeloproliferative Neoplasms.

58 Differences in the risk of thrombosis between type I and II CALR mutations were suggested in one study 4 but failed to reach statistical significance in a larger collaborative study with 1027 patients. 54 A comparison of different leukocyte and platelet activation markers linked with thrombosis in ET patients found no statistically significant differences between CALR mutated and non-mutated patients. 59 Myelofibrotic transformation was reported

also in 6,035 other papers

Leukemic transformation was shown to be significantly lower in patients with CALR -mutated ET compared to those with JAK2 V617F mutated ET using a competing risk approach, but the differences did not reach statistical significance after adjusting for age. 49 A recent retrospective study found that CALR -mutated ET had a lower incidence of leukemic transformation compared to JAK2 V617F mutation and that the leukemic risk was not significantly affected by myelofibrotic transformation in a multivariate analysis. 62 No differences in leukemic transformation in patients with MF 51 , 63 or leukemia-free survival 64 have been found.

also in 111,027 other papers